Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CardioDynamics (CDIC) -- Ignore unavailable to you. Want to Upgrade?

To: David Wiggins who wrote (71)	11/11/1999 8:59:00 AM
From: DENNIS TULLY	Respond to of 201

News: 11/11/99 - CardioDynamics - 'CDIC' - Announces BioZ Study Demonstrating $1 Billion Potential Healthcare Savings -------------------------------------------------------------------------------- SAN DIEGO, Nov 11, 1999 (BW HealthWire) -- Company also Announces Significant Increased Interest in the BioZ at the American Heart Association (AHA) Meeting, Atlanta CardioDynamics International Corporation (Nasdaq:CDIC), manufacturer of BioZ(R) noninvasive digital cardiac output monitoring systems, announced the results of a significant BioZ clinical study at the American Heart Association Meeting held November 7-10, 1999 in Atlanta. The study demonstrates that CardioDynamics' proprietary noninvasive Thoracic Electrical Bioimpedance (TEB) technology can significantly reduce healthcare expenditures by providing an alternative to the costly, risky and invasive Pulmonary Artery Catheter (PAC). The Post-CABG BioZ Study involved cardiopulmonary-bypass surgery patients at the Naval Medical Center in San Diego, California. The study demonstrated the BioZ's ability to reduce over $1 billion in PAC-related expenditures in the 759,000 open heart surgeries performed annually in the United States. Simultaneous cardiac index measurements by the BioZ and PAC were compared over time, and the results revealed outstanding accuracy and clinical equivalence between BioZ and PAC measurements (r = 0.95). Commenting on his study, W. Scott Sageman, M.D., stated, "The Post-CABG BioZ Study is a milestone in hemodynamic monitoring. The potential impact of this study in terms of quality of life and economics is significant, and the data suggest that the BioZ technology may reduce annual healthcare expenditures by over $1 billion. The ability of the BioZ to provide continuous hemodynamic feedback in this setting is an important step towards establishing TEB as a future standard of care." Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "This study further validates the BioZ's role in substantially reducing the estimated $1 trillion spent on healthcare annually in the U.S. by providing a safe, accurate and cost-effective noninvasive alternative for hemodynamic data. The BioZ is being adopted worldwide as the latest monitoring and assessment technology and is becoming the noninvasive method of choice to obtain cardiac function data." The Company also announced physician interest at the AHA Meeting in the BioZ increased over 200% from last year's meeting. The potential sales resulting from these physicians represent over $10 million and will be aggressively pursued by the Company's sales force. Company Description CardioDynamics, with headquarters in San Diego, is committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The Company's primary products, the BioZ(R) System, Portable BioZ(R) and BioZ.com(TM), utilize its proprietary Thoracic Electrical Bioimpedance (TEB) technology to noninvasively obtain data on a wide range of hemodynamic parameters. There are over 300 BioZ(R) systems now in use in major medical centers including the Mayo Clinic (Rochester), UCSF Stanford Health Care, (Palo Alto), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for the BioZ(R) products is estimated to be $4 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the Company's web site at www.cardiodynamics.com. Forward-Looking (Safe Harbor) Statement: Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(TM) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the Company's filings with the SEC, including its 1998 Form 10-KSB. The Company does not undertake to update the disclosures contained in this press release. Copyright (C) 1999 Business Wire. All rights reserved.